Introduction

23
Asthma is a chronic disease of the respiratory tract of in- 24 creasing prevalence in developed societies [1] . The current 25 understanding of allergic asthma is that it results from a break- type switching to IgE, recruitment of eosinophils, basophils 34 and mast cells and production of inflammatory mediators [5] .
35
The murine OVA model of airway hyperresponsiveness ex-36 hibits many of the features of human asthma, including air-37 way hyperreactivity, inflammation and increased serum IgE 38 levels [6, 7] . Th2 cells secreting IL-4, IL-5, and IL-13 play a 39 central role in initiating and sustaining the asthmatic response 40 in this model [8] . While Th2 cells promote airway inflamma-41 tion in asthma, it has been proposed that Th1 cells protect 42 against allergic disease by antagonizing Th2 activity. Infec- 43 tious diseases that induce Th1 type responses, might hamper 44 the development of allergen-specific Th2 cells and prevent 45 allergy [9] .
46
Epidemiological and clinical studies have suggested a link 47 between the relative absence of infectious diseases and the 48 increase in allergic disorders [10, 11] ; this is referred to as the 49 'hygiene hypothesis'. It predicts that infections prevent the in- 50 duction of allergen-specific Th2 cells through antagonism or 51 the induction of regulatory T-cells, particularly during neona-52 elled by respiratory challenge of mice, which correlates well 72 to responses in humans [22] .
73
There has been speculation about the possible promotion 74 of allergy by common childhood vaccinations [23, 24] . A 75 substantial proportion of children predisposed to allergy and 76 asthma may not be fully immunized because of public appre-77 hension surrounding immunization [25] . A number of stud- of atopy in the first years of life [26] . In contrast, Hurwitz 83 and Morgenstern suggested that diphtheria/pertussis/tetanus 84 (DTP) immunization appeared to be associated with an 85 increased risk of subsequent asthma or other allergies 86 [24] . in murine models, but has reduced reactogenicity [29] a Groups of 6-8-week-old female BALB/c mice were immunized (i.p.) and boosted with whole-cell pertussis vaccine (Pw) at −42 and −14 days. On 0 day, mice were either sham infected or infected with B. pertussis (Bp) by aerosol. At 10 and 24 days selected groups were sensitised to OVA by i.p alone or i.p and i.n. routes, respectively. On 35, 36 and 37 days mice were exposed to either saline or OVA by the i.n. route (i.e. 25, 26, and 27 days post-OVA priming and after bacterial clearance). Bacterial burdens in the airways were measured between 0 and 37 days. All other readouts, including plethysmography were performed at 37 days.
b For comparison, further groups of unimmunized (sham immunized) mice were treated as follows: control (Ctrl) mice were sham infected on 0 day and sham sensitised with saline. A second group (Bp) were infected with B. pertussis at 0 day and sham sensitized. The third group (OVA) were sham infected but sensitized with OVA (100 g, i.p.) at 10 and 24 days and again (50 g i.n.) at 24, 35, 36, and 37 days. A separate group (BpOVA) were infected with B. pertussis on 0 day, and sensitized as above. Each experiment was repeated at least twice, on each occasion n > 35 mice per group, bacterial burdens were measured between 0 and 37 days, all other readouts were at 37 days. 
B. pertussis aerosol infection
162
Bacteria from a log-phase culture were resuspended at a con- 
Enumeration of viable bacteria in the lungs
172
Lungs were removed aseptically into 1 ml of sterile phys- and aspiration of 0.5 ml PBS per mouse. This was pooled 185 from five mice (total 2.5 ml) per experimental group. All ex-186 periments were performed at least twice. Diluted BALF was 187 assessed for the presence of cytokines. 
T-cell proliferation assays
198
Spleen cells (2 × 10 6 /ml) from infected, sensitized and 199 control mice (n = 4 or more per group) were tested for 200 in vitro proliferation against heat-inactivated B. pertussis 201 (1 × 10 4 CFU/ml), OVA (20 g/ml), Concanavalin A (Con 202 A) (5 g/ml, positive control), or medium alone (negative 203 control). for 3 min to PBS (baseline) followed by incremental doses 229 (3.3 mg-50 mg/ml) of MCh delivered by aerosol [38] . group using a previously established scoring system [17] .
243
All experiments were performed at least twice. tussis infection and Pw immunization induce a powerful Th1 256 response [29] . In order to examine immune cross-regulation 257 and potential interference with immunization, we tested the 258 effect of OVA sensitization upon the development of a pro-259 tective response to infection in Pw immunized and non-260 immunized mice. Mice received combinations of OVA sen-261 sitization, Pw immunization and aerosol challenge with vir-262 ulent B. pertussis (Table 1) . Groups of mice infected with 263 B. pertussis (Bp and BpOVA) showed similar kinetics of 264 bacterial clearance (Fig. 1) , indicating that OVA sensitiza-265 tion does not influence bacterial clearance rates. Likewise, 266 OVA sensitized and non-sensitized mice that had been im-267 munized prior to bacterial challenge (PwBpOVA and PwBp, 268 respectively) showed identical kinetics of clearance. No bac-269 teria were recovered from the OVA sensitised or control 270 (Ctrl) groups, which were uninfected but received saline by 271 aerosol (Fig. 1) . The bacterial burden in the Bp and BpOVA 272 groups peaked at 10 days and declined thereafter. Pw im-273 munized mice cleared subsequent infection by B. pertus-274 sis by 7 days. In contrast unimmunized mice (Bp and the 275 BpOVA groups) only showed complete bacterial clearance 276 by 35 days (Fig. 1 (Fig. 2C) .
309
OVA sensitization induces high levels of OVA-specific IgE 310 but this is significantly reduced by prior Pw immunization 311 (Fig. 2D) . However, a combination of immunization and in-312 fection prior to OVA sensitization resulted in a significant re-313 duction of IgE (P < 0.05) (Fig. 2D) (Fig. 3A and B) . This was consistent with 326 the protection observed earlier (Fig. 1) and previous data 327 [34] . Pw immunization reduced levels of IL-5, IL-13 and 328 IFN-␥ (Fig. 3A-C ) in all immunized groups suggesting that 329 Pw immunization prevents live B. pertussis enhancement of 330 these indices; mirroring the reduction in OVA-specific IgE 331 (Fig. 2D) . Interestingly, previous results have shown that B. 332 pertussis infection induced specific IL-10 as well as IL-13 333 responses [17] . Here we demonstrate that in contrast to in-334 fection, Pw-immunization resulted in significantly reduced 335 levels of IL-10, and IL-13 (Fig. 3A-D) .
336
To extend these findings, we examined the levels of cy-337 tokines present in bronchoalveolar lavage fluid (BALF) from 338 each group of mice. Pw immunization alone induced little or 339 no detectable cytokines in BALF. As expected, OVA sensiti-340 zation induced high levels of IL-5, -10 and -13 but the levels 341 of IL-10 and -13 in particular, known to rise in infected mice, 342 were reduced in immunized mice that had been infected with 343 B. pertussis (PwBpOVA) (Fig. 4A-D) . tized animals (P < 0.05) (Fig. 5D) . Thus demonstrating that 364 vaccination with Pw protects against B. pertussis exacerba-365 tion of allergic asthma.
366
B. pertussis infection is known to modulate the quality 367 of the inflammatory influx of the respiratory tract, with a 368 marked reduction in eosinophil numbers accompanied by 369 varying degrees of epithelial hyperplasia, mucus metaplasia, 370 and airway pathology [17] . Lung tissue was assessed histo-371 logically (Table 2) . Minimal pathology was observed in mice 372 immunized with Pw or those immunized and infected with 373 B. pertussis (PwBp) (Fig. 6A and B) . Pw and OVA sensitized 374 (PwOVA) mice illustrated moderate mural and peri-airway 375 inflammation with accompanying mild mucus metaplasia and 376 moderate hyperplasia of the epithelium (Fig. 6C) . The com-377 bination of Pw immunization, B. pertussis infection and OVA 378 sensitization did not show enhanced pathology but only mod-379 erate mucus metaplasia and moderate hyperplasia of the ep-380 ithelium (Fig. 6D) . Given that previous work has shown that 381 B. pertussis infection in combination with OVA sensitization 382 (BpOVA) displayed more severe airway inflammation with 383 a greater degree of both epithelial hyperplasia and mucous 384 metaplasia, it can be clearly seen here that Pw immuniza-385 tion reduces the severity of airway pathology (Fig. 6D) reduces pulmonary resistance as indicated by plethysmogra-387 phy (Fig. 5D) . A semi-quantitative score (− absent, + mild, ++ moderate, +++ severe) was assigned to features of airway pathology observed according to previously described criteria [17] . a Peri-airway/vascular inflammation was assessed in terms of overall degree and of numbers of infiltrating eosinophils (E), neutrophils (N), lymphocytes, plasma cells and macrophages (L), mast cells (M) and in terms of circumscribing fibrosis (F).
b Inflammation extending into surrounding pulmonary interstitium and alveolar spaces. [17]. We demonstrate that Pw immunization protects against 399 this as well as reducing airway hyperresponsiveness.
400
The prevalence of asthma and allergic disease has in-401 creased in many countries [39, 40] and there has been spec- asthma and allergies in U.S. children [24] .
